Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
Anne TierensNira Arad-CohenDaniel CheukBarbara De MoerlooseJose Maria Fernandez NavarroHenrik HasleKirsi JahnukainenKristian Løvvik Juul-DamGertjan J L KaspersZanna KovalovaBirgitte LausenUlrika Norén-NyströmJosefine PalleRamune PasaulieneCornelis J H PronkKadri SaksBernward ZellerJonas AbrahamssonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The intensification of induction therapy with risk stratification on the basis of response to induction and hSCT for high-risk patients led to improved outcomes. Mitoxantrone had a superior anti-leukemic effect than liposomal daunorubicin.